NEW YORK (GenomeWeb News) – The German biotech company Kinaxo Biotechnologies, a spinout of the Max Planck Institute, and Bayer Vital announced today that they have formed a collaboration to identify novel phosphoproteomics biomarkers for predicting cancer treatment outcomes.

The researchers plan to use Kinaxo's quantitative phosphoproteomics technology, PhosphoScout, to find and quantify phosphorylation sites as part of a clinical trial conducted by Bayer Vital on the use of oral anti-cancer drug sorafenib (Nexavar) in acute myeloid leukemia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Vivek Murthy is no longer the surgeon general of the US, the Associated Press reports.

People around the globe took to the streets to support science — some with signs.

Parents who learn of their increased genetic risk of disease also contend with telling their children about theirs, the New York Times writes.

In PLOS this week: loci linked to body mass index measurements, long non-coding RNA expression and urothelial carcinoma prognosis, and more.